Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: To determine the maximum tolerated dose (MTD) of vorinostat, a histone deacetylase inhibitor, given concurrently with stereotactic radiosurgery (SRS) to treat non-small cell lung cancer (NSCLC) brain metastases. Secondary objectives were to determine toxicity, local failure, distant intracranial failure, and overall survival rates.
Materials And Methods: In this multicenter study, patients with 1 to 4 NSCLC brain metastases, each ≤2 cm, were enrolled in a phase 1, 3 + 3 dose escalation trial. Vorinostat dose levels were 200, 300, and 400 mg orally once daily for 14 days. Single-fraction SRS was delivered on day 3. A dose-limiting toxicity (DLT) was defined as any Common Terminology Criteria for Adverse Events version 3.0 grade 3 to 5 acute nonhematologic adverse event related to vorinostat or SRS occurring within 30 days.
Results: From 2009 to 2014, 17 patients were enrolled and 12 patients completed study treatment. Because no DLTs were observed, the MTD was established as 400 mg. Acute adverse events were reported by 10 patients (59%). Five patients discontinued vorinostat early and withdrew from the study. The most common reasons for withdrawal were dyspnea (n=2), nausea (n=1), and fatigue (n=2). With a median follow-up of 12 months (range, 1-64 months), Kaplan-Meier overall survival was 13 months. There were no local failures. One patient (8%) at the 400-mg dose level with a 2.0-cm metastasis developed histologically confirmed grade 4 radiation necrosis 2 months after SRS.
Conclusions: The MTD of vorinostat with concurrent SRS was established as 400 mg. Although no DLTs were observed, 5 patients withdrew before completing the treatment course, a result that emphasizes the need for supportive care during vorinostat administration. There were no local failures. A larger, randomized trial may evaluate both the tolerability and potential local control benefit of vorinostat concurrent with SRS for brain metastases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijrobp.2017.04.041 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Explainable deep learning framework for brain tumor detection: Integrating LIME, Grad-CAM, and SHAP for enhanced accuracy.
Med Eng Phys
October 2025
Biomedical Device Technology, Istanbul Aydın University, Istanbul, 34093, Istanbul, Turkey. Electronic address:
Deep learning approaches have improved disease diagnosis efficiency. However, AI-based decision systems lack sufficient transparency and interpretability. This study aims to enhance the explainability and training performance of deep learning models using explainable artificial intelligence (XAI) techniques for brain tumor detection.
View Article and Find Full Text PDFTwo-Step Semi-Automated Classification of Choroidal Metastases on MRI: Orbit Localization via Bounding Boxes Followed by Binary Classification via Evolutionary Strategies.
AJNR Am J Neuroradiol
September 2025
From the Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America (J.S.S., B.M., S.H., A.H., J.S.), and Department of Aerospace Engineering, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India (H.S.).
Background And Purpose: The choroid of the eye is a rare site for metastatic tumor spread, and as small lesions on the periphery of brain MRI studies, these choroidal metastases are often missed. To improve their detection, we aimed to use artificial intelligence to distinguish between brain MRI scans containing normal orbits and choroidal metastases.
Materials And Methods: We present a novel hierarchical deep learning framework for sequential cropping and classification on brain MRI images to detect choroidal metastases.
Towards a definition of an existential approach in cancer patients: a co-produced scoping review.
PLoS One
September 2025
Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands.
Background: Attention to existential needs has become part of daily treatment. Studies have described the concepts of existential experiences and existential interventions. However, a consensus or conceptual clarity regarding an existential approach in cancer patients is currently missing.
View Article and Find Full Text PDFClinical-pathological patterns and prognosis of young women with breast cancer brain metastases: a single-center retrospective study.
J Neurooncol
September 2025
Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
Purpose: Breast cancer (BC) is the most frequent cancer among women and the second leading cause of central nervous system (CNS) metastases. While the epidemiology of CNS metastases from BC has been well described, little is known about the treatment patterns and outcomes of young women < 40 years of age with BC that is metastatic to the CNS.
Methods: In this retrospective analysis, we identified patients with metastatic breast cancer (MBC) to the CNS who were treated at the Sunnybrook Odette Cancer Center, Toronto, Canada between 2008 and 2018.
Impact of weight classes on feasibility, safety, and efficacy of awake craniotomy for brain lesions within eloquent areas.
Neurosurg Rev
September 2025
Service de Neurochirurgie, GHU-Paris Psychiatrie et Neurosciences, Site Sainte Anne, Paris, F-75014, France.
Awake craniotomy is the gold standard to achieve maximal safe resection of brain lesions located within eloquent areas. There are no established guidelines to assess patient's eligibility for awake craniotomy by weight class. This study assesses feasibility, safety, and efficacy of awake surgery by weight classes through an observational, retrospective, single-institution cohort analysis (2010-2024) of 526 awake craniotomies.
View Article and Find Full Text PDF